NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
BioVie Inc. BIVI
13 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
EPS · FY24
$-12.12
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-101.6%
Net margin · FY24
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2024 · full 13-year series below
Revenue
Net income
Per share
USD -12.12
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-101.6%
Return on equity, FY2024
ROE
Operating margin—
Net margin—
Return on assets-75.0%
Each USD of equity lost 102 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2024
Change, 5 years+13.1%
Change, 10 years—
The share count grew 13% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 21.6M
total assets, end of FY2024
Total assetsUSD 21.6M
EquityUSD 19.0M
CashUSD 17.5M
Current ratio9.10×
Equity funds 88% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
·
·
·
·
·
·
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.1
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−12.12
−73.05
−15.47
−1.06
−14.82
−6.85
−0.98
−0.03
−0.01
0.00
0.00
0.00
0.00
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−101.6
−208.3
−528.7
−598.2
·
·
−218.0
−380.5
−86.6
−46.4
−397.4
−97.2
−3.6
Shares out B
0.00
0.00
0.00
0.02
0.02
0.01
0.00
0.10
0.09
0.09
0.09
0.09
0.09
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
32 of 35
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 2 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed